Promoter methylation analysis of CDH1 and p14ARF genes in patients with urothelial bladder cancer

Creative Commons License

Bayramov B., Güneş S., Buyukalpelli R., Aydin O., Henkel R.

ONCOTARGETS AND THERAPY, vol.11, pp.4189-4196, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 11
  • Publication Date: 2018
  • Doi Number: 10.2147/ott.s158259
  • Journal Name: ONCOTARGETS AND THERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.4189-4196
  • Keywords: biomarker, CDH1, urine cytology, urothelial bladder cancer, p14ARF, urine, E-CADHERIN GENE, DNA METHYLATION, MULTIPLE GENES, TUMOR-TISSUES, RASSF1A GENES, VOIDED URINE, HYPERMETHYLATION, BIOMARKERS, P16, ARF
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

Background/aim: Urothelial bladder cancer arises from the accumulation of multiple epigenetic and genetic changes. We aimed to investigate the specificity and sensitivity of gene-specific promoter methylation of CDH1 and p14ARF genes in the early diagnosis of bladder cancer and compare those with other diagnostic tests in our population.